Updated daily
Drug recalls
Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.
Class IITerminatedSep 14, 2016Dextroamphetamine SaccharateUnit Dose Mispackaging; blister cavities may contain more than one tablet /capsuleAmerisource Health Services · D-1484-2016Class IITerminatedSep 14, 2016Dextroamphetamine SaccharateUnit Dose Mispackaging; blister cavities may contain more than one tablet /capsuleAmerisource Health Services · D-1483-2016Class IITerminatedSep 14, 2016Dextroamphetamine SaccharateUnit Dose Mispackaging; blister cavities may contain more than one tablet /capsuleAmerisource Health Services · D-1482-2016Class IITerminatedSep 14, 2016Dextroamphetamine SaccharateUnit Dose Mispackaging; blister cavities may contain more than one tablet /capsuleAmerisource Health Services · D-1481-2016Class IITerminatedSep 14, 2016Methylprednisolone Acetate/Lidocaine HCl 40/10 mg/mL InjectionLack of Processing Controls: Isomeric Pharmacy Solution, LLC announces a voluntary field action for the Methylprednisolone Acetate/Lidocaine HCl 40/10 mg/mL Injection...Isomeric Pharmacy Solution, LLC · D-1480-2016Class IIITerminatedSep 14, 2016Selegiline HCL Tablets USP 5mgStason Pharmaceuticals is recalling Selegiline HCl tablets, USP 5mg 60 count bottle due to an out of specification result for dissolution of stability samples.Stason Pharmaceuticals, Inc. · D-1479-2016Class IIITerminatedSep 7, 2016CLINIQUE moisture surge tinted moisturizer broad spectrum SPF 15Subpotent Drug: Two of the active sunscreen ingredients, octinoxate and octisalate, are below the specifications for assay.Clinique International · D-1478-2016Class IIITerminatedSep 7, 2016CLINIQUE moisture surge tinted moisturizer broad spectrum SPF 15Subpotent Drug: Two of the active sunscreen ingredients, octinoxate and octisalate, are below the specifications for assay.Clinique International · D-1477-2016Class IIITerminatedSep 7, 2016CLINIQUE moisture surge tinted moisturizer broad spectrum SPF 15Subpotent Drug: Two of the active sunscreen ingredients, octinoxate and octisalate, are below the specifications for assay.Clinique International · D-1476-2016Class IIITerminatedSep 7, 2016CLINIQUE moisture surge tinted moisturizer broad spectrum SPF 15Subpotent Drug: Two of the active sunscreen ingredients, octinoxate and octisalate, are below the specifications for assay.Clinique International · D-1475-2016Class IIITerminatedSep 7, 2016CLINIQUE moisture surge tinted moisturizer broad spectrum SPF 15Subpotent Drug: Two of the active sunscreen ingredients, octinoxate and octisalate, are below the specifications for assay.Clinique International · D-1474-2016Class IIITerminatedSep 7, 2016CLINIQUE moisture surge tinted moisturizer broad spectrum SPF 15Subpotent Drug: Two of the active sunscreen ingredients, octinoxate and octisalate, are below the specifications for assay.Clinique International · D-1473-2016Class IIITerminatedAug 31, 2016Hydrocortisone and acetic acid otic solutionFailed Impurities/Degradation Specifications: Out of specification (OOS) results for related compound G were obtained at 12-month (at expiry) stability time-point for...Actavis Inc · D-1472-2016Class IIITerminatedAug 31, 2016Acetasol HCFailed Impurities/Degradation Specifications: Out of specification (OOS) results for related compound G were obtained at 12-month (at expiry) stability time-point for...Actavis Inc · D-1471-2016Class IITerminatedAug 31, 2016Amoxicillin for Oral Suspension USPSuperpotent drug: Out of specification test result for assay during stability testing.Teva North America · D-1470-2016Class IIITerminatedAug 31, 2016Desoximetasone Gel USPFailed impurities/degradation specifications: product was out of specification for unknown impurity at the 9 month stability time pointAkorn, Inc. · D-1469-2016Class IITerminatedAug 31, 2016Amlodipine Besylate TabletsCGMP Deviations: Pharmaceuticals were produced and distributed with active ingredients not manufactured according to Good Manufacturing Practices.Mylan Institutional, Inc. (d.b.a. UDL Laboratories) · D-1468-2016Class IITerminatedAug 31, 2016Amlodipine Besylate TabletsCGMP Deviations: Pharmaceuticals were produced and distributed with active ingredients not manufactured according to Good Manufacturing Practices.Mylan Institutional, Inc. (d.b.a. UDL Laboratories) · D-1467-2016Class IITerminatedAug 31, 2016Amlodipine Besylate TabletsCGMP Deviations: Pharmaceuticals were produced and distributed with active ingredients not manufactured according to Good Manufacturing Practices.Mylan Institutional, Inc. (d.b.a. UDL Laboratories) · D-1466-2016Class IIITerminatedAug 31, 2016Urea (50% Urea in a Cream Base)Crystallization; complaints received by the manufacturer of crystals forming in productExact-Rx Inc · D-1465-2016Class IIICompletedAug 31, 2016Remeven CreamCrystallization; Complaints that cream appears to have crystallizedStratus Pharmaceuticals Inc · D-1464-2016Class IITerminatedAug 31, 2016Sermorelin 6 mg and Sermorelin 6 mg/GHRP-2 InjectionLack of Assurance of SterilityTalon Compounding Pharmacy · D-1463-2016Class IITerminatedAug 31, 2016Human Chorionic Gonadotropin InjectionLack of Assurance of SterilityTalon Compounding Pharmacy · D-1462-2016Class IITerminatedAug 24, 2016Venlafaxine HCL ER Capsule USPFailed Dissolution Specifications: out of specification dissolution results in retained samplesZydus Pharmaceuticals USA Inc · D-1461-2016Class IITerminatedAug 24, 2016Venlafaxine HCL ER Capsule USPFailed Dissolution Specifications: out of specification dissolution results in retained samplesZydus Pharmaceuticals USA Inc · D-1460-2016Class IITerminatedAug 24, 2016Venlafaxine Hydrochloride Extended-Release CapsulesFailed Dissolution Specifications: Out-of-specification results in retained sample.Golden State Medical Supply Inc. · D-1459-2016Class IITerminatedAug 24, 2016Venlafaxine Hydrochloride Extended-Release CapsulesFailed Dissolution Specifications: Out-of-specification results in retained sample.Golden State Medical Supply Inc. · D-1458-2016Class IITerminatedAug 24, 2016Glipizide 2.5 mg Extended-release tabletsFailed Dissolution Specifications: Glipizide 2.5 mg ER Tablets exceeded dissolution specification rates for the 10 hour testing point.Actavis Inc · D-1457-2016Class IITerminatedAug 17, 2016Zinc AcetateDoes not meet monograph: product exhibits lead levels in excess of the USP monograph limits.Spectrum Laboratory Products, Inc. · D-1456-2016Class IITerminatedAug 17, 2016Albuterol Sulfate SyrupPresence of Foreign Substance; presence of black particles describes generically as cellulose-based bundles of brown fibrous material.Teva North America · D-1455-2016Class IITerminatedAug 10, 2016Betamethasone Acetate / Betamethasone Sodium Phosphate Injectable SuspensionLack of processing controls: Isomeric Pharmacy Solution, LLC is recalling Betamethasone Acetate / Betamethasone Sodium Phosphate 7 mg/mL INJ SUSP because of the...Isomeric Pharmacy Solution, LLC · D-1454-2016Class IIITerminatedAug 10, 2016Children's Qnasl 40 mcgFailed Content Uniformity Specifications: out of specification test result for spray content uniformity.Teva North America · D-1453-2016Class IITerminatedAug 10, 2016Oxygen Nasal WashMarketed Without An Approved NDA/ANDA: product is an unapproved drug due to nasal decongestant claims as well as not complying with the nasal decongestant final...Let's Talk Health, Inc. · D-1452-2016Class IIITerminatedAug 3, 2016mitoXANTRONE Injection USPFailed Impurities/Degradation Specifications: High out of specification results for Impurity D.Teva North America · D-1451-2016Class IITerminatedAug 3, 2016Oxacillin for InjectionPresence of Particulate Matter; The firm received two product complaints for small, dark particulate matter identified in solution post reconstitution.Sagent Pharmaceuticals Inc · D-1450-2016Class IIITerminatedAug 3, 2016Divalproex Sodium Delayed-release Tablets USPFailed Tablet/Capsule SpecificationsTeva North America · D-1449-2016Class IITerminatedAug 3, 2016Dextroamphetamine Sulfate Extended-Release CapsulesFailed Dissolution SpecificationsActavis Inc · D-1448-2016Class IITerminatedAug 3, 2016Acetylcyst 10% OPHT SOLLack of Assurance of Sterility: Sterile products were not produced in a controlled, sterile environment.Medicap Pharmacy · D-1447-2016Class IIITerminatedJul 27, 2016buPROPion Hydrochloride Extended Release Tablets USPFailed Dissolution SpecificationsSun Pharmaceutical Industries, Inc. · D-1446-2016Class IITerminatedJul 27, 2016Bactroban OintmentPenicillin Cross ContaminationGlaxoSmithKline, LLC · D-1445-2016